Advances in the development of new biomarkers for Alzheimer's disease | Translational Neurodegeneration | Full Text
Fc effector of anti-Aβ antibody induces synapse loss and cognitive deficits in Alzheimer's disease-like mouse model | Signal Transduction and Targeted Therapy
JPM | Free Full-Text | Biomarkers for Alzheimer's Disease Early Diagnosis
Synergistic Association between Plasma Aβ1–42 and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia | ACS Chemical Neuroscience
New Alzheimer's Biomarkers may Support Early Diagnosis
Amyloid‐β oligomers in cellular models of Alzheimer's disease - Fontana - 2020 - Journal of Neurochemistry - Wiley Online Library
Biomedicines | Free Full-Text | Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
JPM | Free Full-Text | Current Biomarkers for Alzheimer's Disease: From CSF to Blood
Structural Dynamics of Amyloid-β Protofibrils and Actions of Anti-Amyloid-β Antibodies as Observed by High-Speed Atomic Force Microscopy | Nano Letters
Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre‐clinical AD, amnestic mild cognitive impairment and late‐stage AD - Tramutola - 2015 -
An App knock-in rat model for Alzheimer's disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairments | Cell Research
The Amyloid-β Pathway in Alzheimer's Disease | Molecular Psychiatry
Cells | Free Full-Text | Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview
ADPD 2023: Alzheimer's Disease Therapeutics, Diagnostics & Mechanisms
Nasal administration of anti-CD3 monoclonal antibody ameliorates disease in a mouse model of Alzheimer's disease | PNAS
Amyloid-β (Aβ) marker expression and Aβ aggregation in the... | Download Scientific Diagram
Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future | Signal Transduction and Targeted Therapy
Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer's disease | Translational Psychiatry
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer's Disease Therapeutics
Frontiers | Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients
Decreased salivary lactoferrin levels are specific to Alzheimer's disease - eBioMedicine
Biomolecules | Free Full-Text | Microvascular Contributions to Alzheimer Disease Pathogenesis: Is Alzheimer Disease Primarily an Endotheliopathy?
Blood‐based biomarkers for Alzheimer's disease | EMBO Molecular Medicine
